<DOC>
	<DOCNO>NCT01928199</DOCNO>
	<brief_summary>The purpose study determine whether sitagliptin effective preventing development new-onset diabetes kidney transplant ( NODAT ) . Up one-third previously non-diabetic patient develop NODAT kidney transplant . Corticosteroids calcineurin inhibitor two commonly utilized anti-rejection medication contribute diabetes development multiple mechanism ; include decreased insulin production pancreas . Sitagliptin oral medication result increase insulin secretion . We hypothesize administration sitagliptin transplant recipient identify risk diabetes development reduce incidence severity NODAT .</brief_summary>
	<brief_title>Efficacy Study Sitagliptin Prevent New-onset Diabetes After Kidney Transplant</brief_title>
	<detailed_description>This single-center , randomize , double-blind trial evaluate efficacy sitagliptin prevent development new-onset diabetes transplant ( NODAT ) previously non-diabetic patient post-operative hyperglycemia follow living-donor deceased-donor kidney transplant . In trial , previously non-diabetic adult patient hyperglycemia ( random blood sugar &gt; 200mg/dL ) first 72 hour follow kidney transplant screen determine eligibility base inclusion/exclusion criterion . Patients meet study entry criterion stratify base HbA1c ( &lt; 5.7 5.7-6.4 % ) randomize 1:1 ratio one two treatment group : sitagliptin versus placebo . Fifty patient ( 25 per group ) enrol . Dosing period 3 month time study drug discontinue patient follow additional 3 month period . Study visit occur 0 , 1 , 3 6 month . A HbA1c 2-hour oral glucose tolerance test ( OGTT ) obtain 3 6 month study visit . Screening period ( Visit 1 ) All patient present living-donor deceased donor kidney transplant medical history , medication history , vital sign , height , weight , body mass index , physical exam , random blood sugar ( BS ) , HbA1c EKG do part routine pre-transplant protocol Barnes Jewish Hospital . Patients hyperglycemia , define random blood sugar ≥ 200 mg/dL , first 72 hour kidney transplant screen determine eligibility study base inclusion exclusion criterion . Randomization ( Visit 2 ) Patients meet study entry criterion consent study participation stratify base HbA1c ( &lt; 5.7 5.7-6.4 % ) block randomize block eight 1:1 ratio sitagliptin versus placebo . Sitagliptin dose 100mg/day , adjust per creatinine clearance tolerability . Patients instruct licensed diabetic educator proper measurement record fast post-prandial blood sugar . Subjects provide log , standard glucometer test strip maintain blood sugar log post-discharge . Visit 2 occur within 24 hour Visit 1 . Drug dose period ( Visits 3-4 ) Sitagliptin placebo continue 3 month post-transplant , time study medication discontinue collect subject . At 1 3 month visit , vital sign , height , weight , BMI obtain . A physical exam perform . Blood sugar log provide patient review adverse effect record . At 3 month visit ( Visit 4 ) , HbA1c , 2-hour OGTT , fast C-peptide insulin level obtain . Follow-up ( Visit 5 ) At 6 month final visit , 3 month follow discontinuation study medication , vital sign , height , weight , BMI , HbA1c , 2-hour OGTT , fast C-peptide insulin level obtain . A physical exam perform . Blood sugar log provide patient review adverse effect record .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Adult ( ≥18 yo ) recipient livingdonor decease donor kidney transplant 2 . Blood sugar ≥ 200 mg/dL first 72 hour transplant 3 . No history diabetes prior treatment insulin oral hypoglycemic agent 1 . A1c ≥6.5 % measure immediately pretransplant 2 . Recipient simultaneous kidneypancreas , kidneyliver , kidneyheart , kidneylung transplant 3 . Prior nonrenal solid organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>diabetes</keyword>
	<keyword>transplant</keyword>
	<keyword>kidney</keyword>
</DOC>